Elgi Equipments Ltd Q2 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/qu90ckfpq9ygt2qqem1efyy6.pdf

Key Takeaways


Margin Walk: Pricing Gains, Fixed-Cost Normalization

Jairam Varadaraj: "We are not going to give away prices which are based on cost increases, but if there are cost increases that we have overestimated and to that extent, we need to correct prices, we will do so. So the idea is growth and that too profitably."

Europe: The Deliberate Investment That Weighs on Consolidated Profits


Geographic Performance: U.S. Leads, India Holds Without Oxygen Boost


Inventory & Cash Flow: The Cost of Availability


Demand Outlook: Broad Inquiries, Uncertain Conversion

Jairam Varadaraj: "We have got to keep in mind what happened with commodity prices in a very short period in the month of December in 2020. So the world has demonstrated that things can change quite rapidly, quite drastically, so we are keeping our fingers cross, so we still think that Q3 will be good, but we have to wait and see, so there is a bit of a caution on that."

Motor Plant & Capex: Delayed Again, Vendor Replaced


Strategy & Positioning: Profitable Growth Over Margin Extraction

Jairam Varadaraj: "Can we remain the same level of topline and achieve 16% that is a no and I would actively discourage that, because then you are just dropping up, you are extracting margins from the market, you are just milking it, you are not growing it."

Guidance & Commitments

CommitmentSpecificsTimeline
Fixed costsNormalized levels sustained going forwardOngoing
Inventory unwindProgressive reduction across all regions; cash flow improvement before inventory-level results visibleTwo-to-three-month transition
Debt reductionNet closing debt to come down significantly from ~₹155 CroresNo specific quarter or FY-end number given
Motor plant critical machineDelivery from new vendorQ4 FY23
Motor plant full capacityFull capacity availableNext year (FY24)
European breakevenOperations reach breakevenFY2025 (delayed one year from original FY2024 plan by COVID)
European hiringNo further overhead hiring unless justified by associated revenueOngoing
Margin target16% operating marginBy FY2025–2026; currently ~14.5%
Pricing reviewAnalytical review of costs and future outlook before deciding on price changesUnderway, no deadline given

Key Metrics

MetricQ2 FY23
Consolidated revenue₹738 cr, +12% YoY reported; +18% YoY excluding oxygen concentrators
Standalone revenue₹448 cr
Standalone PBT₹95 cr
Consolidated PBT₹104 cr
Operating profit margin15.2%
EBITDA~₹110 cr; management estimate of what it should have been was ~₹160 cr, a ~₹50 cr shortfall due to fixed costs normalizing
Volume growth (consolidated)~8%
Volume growth (India, ex-oxygen)~8%; ~2–3% including oxygen
Net closing debt~₹155 cr, up ₹65 cr from ~₹90 cr in March 2022
Inventory increase~₹150 cr during H1 FY23
Capex spent in H1 FY23~₹25 cr; full-year expectation ₹50–55 cr
Aftermarket revenue share22–23% of global consolidated revenue
Domestic revenue share40–42% of consolidated revenue; last year was ~55%
Currency impact on revenue~1% net favorable; dollar gains offset by euro
Europe investment planLosses well below the originally planned €20 mn (~₹160 cr) mid-through losses; breakeven now targeted FY2025